HbA1c Variation Study

Diabetes Mellitus Clinical Trial

Official title:

HbA1c Variation Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05189938
• Other study ID #: ADC-US-RES-21212
• Status: Active, not recruiting
• Start date: December 20, 2021
• Est. completion date: June 2024

Study information

• Verified date: January 2024
• Source: Abbott Diabetes Care
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To evaluate the relationship between glycated hemoglobin (HbA1c) and average glucose levels using continuous glucose monitoring.

Description:

This is a non-pivotal , non-randomized, single-arm, multi-center, prospective, non-significant risk study to evaluate the relationship between glycated hemoglobin (HbA1c) and average glucose levels. Up to approximately 600 subjects will be enrolled who will have fourteen (14) study visits over the course of approximately six (6) months. During each visit the subject will have blood samples drawn for documentation of their HbA1c level. Subjects will also be required to wear Professional FreeStyle Libre Flash Glucose Monitoring System(s) to record blood glucose levels through the duration of the study. During Visits 1 and 14, Venous sample for CBC, biochemistry, haemoglobinopathy screen, hematology, liver function and iron panels will be collected.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 600
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years and older

Eligibility

Inclusion Criteria:

1. Subject must have type 1 or type 2 diabetes.

2. Subject is at least 4 years old.

3. Point-of-care (POC) HbA1C of 3.0%-15.5% (9 mmol/mol - 146 mmol/mol)

4. Subject must be able to read and understand English.

5. In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.

6. Subject must be available to participate in all study visits.

7. Subject must be willing and able to provide written signed and dated informed consent.

8. Subjects age 4 - 17: Parent or guardian must be willing and able to provide written signed and dated informed consent.

9. Subjects age 11 - 17 Subject must be willing and able to provide written signed and dated informed assent.

Exclusion Criteria:

10. Subject is currently undergoing dialysis or planning to receive dialysis during the course of the study

11. History of blood transfusion in the last 3 months or planned blood transfusion during the course of the study.

12. Subject is currently planning to undergo a major medical intervention expected to significantly alter red cell life span, i.e. chemotherapy, major surgery requiring blood transfusions, etc.

13. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.

14. Subjects age 18 and older: Subject is known to be pregnant, attempting to conceive or is not willing and able to practice birth control during the study duration study (applicable to female subjects only). Subjects age 17 and younger: Subject is known to be pregnant at the time of study enrollment or is planning to become pregnant during the study (applicable to female subjects only).

15. Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.

16. Subject has a pacemaker or any other neurostimulators.

17. Subject has concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff.

18. Subject is currently participating in another interventional clinical trial.

19. Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Diagnostic Test:
• HBA1c data and glucose levels
All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.

Locations

Country	Name	City	State
United Kingdom	University Hospital Birmingham	Birmingham
United Kingdom	Bradford Royal Infirmary	Bradford
United Kingdom	Royal Derby Hospital	Derby
United Kingdom	Edinburgh Royal Infirmary	Edinburgh
United Kingdom	Northwick Park Hospital	Harrow
United Kingdom	Hull Royal Infirmary	Hull
United Kingdom	St James University Hospital	Leeds
United Kingdom	Leicester General Hospital	Leicester
United Kingdom	Manchester Royal Infirmary	Manchester
United Kingdom	Nottingham Children's Hospital & Queen's Medical Centre	Nottingham
United Kingdom	Royal Berkshire Hospital	Reading
United Kingdom	Northern General Hospital	Sheffield
United Kingdom	Ealing Hospital	Southall
United Kingdom	The Royal London Hospital	Whitechapel
United States	Billings Clinic	Billings	Montana
United States	Eastside Research Associates	Redmond	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Diabetes Care

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establish a relationship between laboratory-derived HbA1c and average glucose levels	This is an observational data collection study, where the goal is to gather data to establish the relationship between laboratory-derived HbA1c and average glucose levels.	six (6) months